close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Terns Pharmaceuticals, Inc. - Common Stock (NQ:TERN)

17.07 +3.04 (+21.67%)
Streaming Delayed Price Updated: 1:47 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Terns Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Henry Schein, Sanmina, Wingstop, Waters And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Which stocks are moving on Monday?
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Kenvue, IDEXX Laboratories, Freshpet And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades
Terns Pharmaceuticals shares rise after TERN-701 shows a 75% response rate in the CML trial, and William Blair upgrades the stock to Outperform. 
Via Benzinga
Top movers analysis in the middle of the day on 2025-11-03: top gainers and losers in today's session.
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Gapping stocks in Monday's session
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Why Is Terns Pharmaceuticals Stock Trading Lower After Obesity Trial Data?
Terns Pharmaceuticals announces 12-week Phase 2 results for oral obesity drug TERN-601, showing up to 4.6% weight loss but reporting cases of drug-induced liver injury. 
Via Benzinga
Netflix Posts Downbeat Earnings, Joins Aveanna Healthcare, Texas Instruments And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Why Intuitive Surgical Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Which stocks are moving after the closing bell on Tuesday?
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
2 Under-the-Radar Stocks That Could Soar
They could ride the wave of the hottest therapeutic area in the industry. 
Via The Motley Fool
Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025
Webinar to be held on Wednesday, September 3, 2025 at 4:30 p.m. ET 
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the... 
Via MarketMinute
Topics Economy
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors
Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates. 
Via Benzinga
Terns (TERN) Q2 Net Loss Narrows 16%
Via The Motley Fool
Topics Intellectual Property
Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today